...
首页> 外文期刊>Nature neuroscience >Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model.
【24h】

Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model.

机译:用siRNA靶向BACE1可改善转基因模型中的阿尔茨海默氏病神经病理。

获取原文
获取原文并翻译 | 示例
           

摘要

In Alzheimer disease, increased beta-secretase (BACE1) activity has been associated with neurodegeneration and accumulation of amyloid precursor protein (APP) products. Thus, inactivation of BACE1 could be important in the treatment of Alzheimer disease. In this study, we found that lowering BACE1 levels using lentiviral vectors expressing siRNAs targeting BACE1 reduced amyloid production and the neurodegenerative and behavioral deficits in APP transgenic mice, a model of Alzheimer disease. Our results suggest that lentiviral vector delivery of BACE1 siRNA can specifically reduce the cleavage of APP and neurodegeneration in vivo and indicate that this approach could have potential therapeutic value for treatment of Alzheimer disease.
机译:在阿尔茨海默氏病中,增加的β-分泌酶(BACE1)活性与淀粉样前体蛋白(APP)产品的神经变性和积累有关。因此,BACE1的失活在阿尔茨海默氏病的治疗中可能很重要。在这项研究中,我们发现使用表达靶向BACE1的siRNA的慢病毒载体降低BACE1的水平可降低淀粉样蛋白的产生,以及APP转基因小鼠(阿尔茨海默病模型)的神经变性和行为缺陷。我们的结果表明,慢病毒载体递送BACE1 siRNA可以特异性减少APP的裂解和体内神经变性,并表明该方法可能对治疗阿尔茨海默氏病具有潜在的治疗价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号